We’re back from Paris and what a few days it’s been. EuroPCR always hits the sweet spot: not too big, not too small, just the right setting to meet both familiar and new faces.
Our CEO Gery de Jong shared: “It was a strong moment for our network. This congress isn’t just about results; it’s about discussing options. What’s smart, what fits and how can we make the best decisions for each patient.”
(Live) cases really stood out this year. We attended discussions about complex PCI in TAVI patients and difficult ACS scenarios, and we learned that there’s rarely one solution. Some of the best outcomes come when teams step back and ask each other what’s the right approach for this case?
We also found the sessions on coronary microvascular dysfunction promising, especially treatment strategies using coronary sinus reducers.
So, lots of food for thought and a stronger sense of where the field is going.
Were you there too? What stood out to you?
